RxDoctor Payments Data

Karissa Haugen

Psychiatric/Mental Health · Hermantown, MNNPI 1275124463

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Supernus Pharmaceuticals, Inc. at 24.5% of the total. Among psychiatric/mental health clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$424in general payments, 2019–2025

Across 30 payments — averaging $14.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$104
  • Corium, LLC$78
  • Neurocrine Biosciences, Inc.$63
  • Tempus AI, Inc$29
  • Teva Pharmaceuticals USA, Inc.$29
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$26
  • plus $96 from 7 others

What the payments were for

  • Food & beverage$424100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$424 in reported general payments places this provider in the 90th percentile of 407 psychiatric/mental health providers in Minnesota.

See all psychiatric/mental health providers in Minnesota

Medicare billing

Part B allowed, 2024
$54,433
Medicare patients
45
Services billed
383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$97,271
VraylarCariprazine Hcl11$17,527
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl13$2,446
Risperidone19$1,521
Gabapentin59$1,480
Hydroxyzine Hcl44$1,110
Fluoxetine Hcl38$863
Vilazodone Hcl18$843
Mirtazapine44$782
Quetiapine Fumarate40$752
Trazodone Hcl40$522
Bupropion XlBupropion Hcl12$508
Prazosin Hcl28$441
Venlafaxine Hcl ErVenlafaxine Hcl49$398
Buspirone Hcl38$385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$63$97,27112 claims
AbbVieVraylar$13$17,52711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 407 psychiatric/mental health providers in Minnesota.

Other psychiatric/mental health in Hermantown

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →